Incidence and predictors of retreatment in chronic hepatitis B patients after discontinuation of entecavir or tenofovir treatment.

Te-Ling MaTsung-Hui HuChao-Hung HungJing-Houng WangSheng-Nan LuChien-Hung Chen

Published in: PloS one (2019)

The 5-year retreatment rate was about 50% in HBeAg-positive and HBeAg-negative patients. Discontinuing TDF treatment was an independent factor of retreatment in HBeAg-positive patients.

Keyphrases

end stage renal disease
hepatitis b virus
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
patient reported outcomes
combination therapy
antiretroviral therapy